Prostamax: The Prostate Bioregulator Tetrapeptide in Urological Research

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is Prostamax?

Prostamax is a synthetic tetrapeptide with the amino acid sequence Lys-Glu-Asp-Pro (lysine-glutamic acid-aspartic acid-proline). It is the prostate-targeted bioregulator in the Khavinson peptide series, developed based on peptide fractions isolated from bovine prostate tissue extracts. The earlier extract-based preparation, known as Prostatilen, has been used in some Eastern European countries as a marketed pharmaceutical for prostatitis and benign prostatic hyperplasia (BPH).

Benign prostatic hyperplasia affects approximately 50% of men over age 50 and up to 90% over age 80, making prostate health a major area of male aging research. The development of a prostate-targeted bioregulator reflects the Khavinson school's approach of creating tissue-specific peptide interventions for age-related organ decline. For an overview of bioregulator peptides, see our guide to bioregulator peptides.

Mechanism of Action

Prostamax is proposed to function through the same epigenetic mechanism attributed to other Khavinson bioregulators. The tetrapeptide is hypothesized to enter prostate epithelial and stromal cells, interact with chromatin in a tissue-specific manner, and modulate expression of genes relevant to prostate homeostasis and growth regulation.

• Growth factor modulation: Published studies suggest that Prostamax may influence the expression of growth factors involved in prostatic hyperplasia, including insulin-like growth factor (IGF), fibroblast growth factor (FGF), and transforming growth factor beta (TGF-β).
• Androgen pathway: Some reports describe effects on androgen receptor expression and 5-alpha-reductase activity in prostate tissue, though the data are limited.
• Anti-inflammatory effects: Preclinical studies suggest modulation of inflammatory cytokine expression in prostate tissue, potentially relevant to chronic prostatitis.

Research Findings

Animal Studies

Published studies in aged rats have reported that Prostamax administration reduced histological markers of prostatic hyperplasia, including glandular epithelial proliferation, stromal expansion, and inflammatory infiltration. Some studies reported reduced prostate weight relative to untreated aged controls, with improved tissue architecture approaching younger baseline morphology.

Prostatilen Context

The extract-based predecessor, Prostatilen, has a somewhat broader evidence base, with Russian clinical studies reporting improved urinary symptoms, reduced prostate inflammation markers, and improved quality of life scores in men with chronic prostatitis and BPH. However, these studies generally do not meet Western standards for clinical trial rigor (blinding, placebo control, intention-to-treat analysis), and the transition from complex extract to purified tetrapeptide introduces uncertainty about whether the synthetic peptide reproduces the activity of the whole extract.

Critical Assessment

The same limitations that apply to the Khavinson bioregulator class broadly apply to Prostamax. The evidence base lacks independent replication, the proposed mechanism is unconventional and unconfirmed, and no clinical trials meeting international standards have been published for the synthetic tetrapeptide specifically. Given the availability of well-studied pharmaceutical treatments for BPH and prostatitis (alpha-blockers, 5-alpha-reductase inhibitors, antibiotics), the clinical relevance of Prostamax remains speculative.

Safety and Tolerability

No significant adverse effects have been reported in published animal studies. Prostatilen has a longer track record of human use in Eastern European countries without major safety signals, though post-marketing surveillance data meeting international pharmacovigilance standards are not available for either the extract or the synthetic peptide.

Regulatory Status

Prostamax is not FDA-approved or EMA-approved. Prostatilen (the extract-based product) has been registered in Russia and some other countries as a pharmaceutical for prostatitis treatment. The synthetic tetrapeptide Prostamax is available through supplement channels in some jurisdictions but has not undergone Western regulatory evaluation. Men with urological concerns should consult qualified urologists.